Critical Illness After Hematopoietic Cell Transplantation

NCT07328724 | Not Yet Recruiting

• 1 other identifier: 2025-z259
• Study Type: observational
• Target: 4,000
• Locations: 1 country
• Sites: 6

Brief Summary

This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.

Conditions

Hematopoetic Stem Cell Transplantation; Critical Illness; Ventilated Patients; Transplant Complication

Keywords

hematopoietic cell transplantation; critical illness; management; prognosis; transplant complication

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Overall survival after admission to the intensive care unit.

  Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.

Secondary Outcomes (6)

• Non-relapse mortality

  Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.

• Relapse

  At ICU admission and within 1 year of ICU discharge.

• Transplant complication

  At ICU admission and within 1 year of ICU discharge.

• Organ failure

  At ICU admission and within 1 year of ICU discharge.

• Organ support therapy

  At ICU admission and within 1 year after ICU discharge.

Study Arms (1)

Critically ill patients after hematopoietic cell transplantation

Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are admitted to ICU after undergoing hematopoietic cell transplantation at any of the participating medical centers.

You may qualify if:

• Patients who underwent hematopoietic cell transplantation at any of the participating medical centers.
• Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.

You may not qualify if:

• Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission.
• Unavailable in-ICU clinical outcomes or absent key baseline characteristics.
• Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.

Sponsors & Collaborators

• First Affiliated Hospital of Zhejiang University: collaborator
• First Affiliated Hospital of Harbin Medical University: collaborator
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: collaborator
• Peking University People's Hospital: lead
• Xinqiao hospital of the third military medical university: collaborator
• Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences): collaborator

Study Sites (6)

Peking University People's Hospital

Beijing, China

Location

Xinqiao hospital of the third military medical university

Chongqing, China

Location

First Affiliated Hospital of Zhejiang University

Hangzhou, China

Location

First Affiliated Hospital of Harbin Medical University

Harbin, China

Location

Hematology Hospital of Chinese Academy of Medical Sciences

Tianjin, China

Location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Xiao Hui Zhang, MD

CONTACT

861088324577; zhangxh@bjmu.edu.cn

Peng Zhao, MD

CONTACT

861088324577; ZhaoP@pku.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: December 27, 2025
• First Posted: January 9, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): June 30, 2036
• Study Completion (Estimated): December 31, 2036
• Last Updated: January 9, 2026

Record last verified: 2025-12

Locations

CN (6)